| scholarly article | Q13442814 |
| P50 | author | Ronald Swanstrom | Q62641484 |
| P2093 | author name string | Sook-Kyung Lee | |
| Janera Harris | |||
| P2860 | cites work | Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1 | Q24609814 |
| Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system | Q24628961 | ||
| Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein | Q27639039 | ||
| Structure of the Antiviral Assembly Inhibitor CAP-1 Complex with the HIV-1 CA Protein | Q27647971 | ||
| Complete inhibition of human immunodeficiency virus Gag myristoylation is necessary for inhibition of particle budding | Q28274359 | ||
| Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype | Q28646874 | ||
| Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 | ||
| Viral DNA synthesis defects in assembly-competent Rous sarcoma virus CA mutants. | Q30327614 | ||
| Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag | Q30478394 | ||
| Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease | Q30850215 | ||
| A peptide inhibitor of HIV-1 assembly in vitro | Q33220259 | ||
| Towards the structure of the human immunodeficiency virus: divide and conquer | Q33632676 | ||
| Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences | Q33930053 | ||
| HIV preferentially infects HIV-specific CD4+ T cells | Q33958893 | ||
| The stoichiometry of Gag protein in HIV-1. | Q34328141 | ||
| Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication | Q34364648 | ||
| High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. | Q34420162 | ||
| Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1 | Q36098898 | ||
| Recombination of transfected DNAs in vertebrate cells in culture | Q36269941 | ||
| Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. | Q36650046 | ||
| Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation | Q36944553 | ||
| Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation | Q36958798 | ||
| Human Immunodeficiency Virus Type 1 N-Terminal Capsid Mutants Containing Cores with Abnormally High Levels of Capsid Protein and Virtually No Reverse Transcriptase | Q37060306 | ||
| PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing | Q37089562 | ||
| Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator | Q37256308 | ||
| High-resolution structure of a retroviral capsid hexameric amino-terminal domain | Q39272732 | ||
| Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. | Q39579012 | ||
| Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid Protein | Q39748566 | ||
| Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. | Q40045233 | ||
| Lentiviral vector transduction of a dominant-negative Rev gene into human CD34+ hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication | Q40197225 | ||
| Mutant murine leukemia virus Gag proteins lacking proline at the N-terminus of the capsid domain block infectivity in virions containing wild-type Gag. | Q40326740 | ||
| Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles | Q40357793 | ||
| Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly | Q41047831 | ||
| Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication | Q41981808 | ||
| Dominant negative inhibition of human immunodeficiency virus particle production by the nonmyristoylated form of gag. | Q42688106 | ||
| Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. | Q43698594 | ||
| Antiviral inhibition of the HIV-1 capsid protein | Q44380725 | ||
| Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression | Q44389543 | ||
| The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor | Q45432280 | ||
| HIV-1 capsid mutants inhibit the replication of wild-type virus at both early and late infection phases | Q45759776 | ||
| HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus | Q45843803 | ||
| Inhibiting AIDS in the central nervous system: gene delivery to protect neurons from HIV. | Q45862705 | ||
| Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses | Q46555479 | ||
| Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells | Q46848734 | ||
| Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid | Q54693321 | ||
| Functional dissection of the HIV-1 Rev trans-activator—Derivation of a trans-dominant repressor of Rev function | Q58611466 | ||
| Combination genetic therapy to inhibit HIV-1 | Q77474900 | ||
| Implications for viral capsid assembly from crystal structures of HIV-1 Gag(1-278) and CA(N)(133-278) | Q80280623 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 8536-8543 | |
| P577 | publication date | 2009-06-10 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle | |
| P478 | volume | 83 |
| Q41730903 | A Direct Interaction with RNA Dramatically Enhances the Catalytic Activity of the HIV-1 Protease In Vitro |
| Q40618525 | A Truncated Nef Peptide from SIVcpz Inhibits the Production of HIV-1 Infectious Progeny |
| Q42872702 | A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease |
| Q39214476 | A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells |
| Q34771244 | A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsid |
| Q36292602 | ATP generation in a host cell in early-phase infection is increased by upregulation of cytochrome c oxidase activity via the p2 peptide from human immunodeficiency virus type 1 Gag. |
| Q27324263 | Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors |
| Q51740197 | An RNA-binding compound that stabilizes the HIV-1 gRNA packaging signal structure and specifically blocks HIV-1 RNA encapsidation. |
| Q41816646 | BST-2 Diminishes HIV-1 Infectivity |
| Q42001066 | Clearly different mechanisms of enhancement of short-lived Nef-mediated viral infectivity between SIV and HIV-1. |
| Q33761008 | Cryo electron tomography of native HIV-1 budding sites |
| Q34435796 | Development of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs |
| Q33791156 | Distinct nucleic acid interaction properties of HIV-1 nucleocapsid protein precursor NCp15 explain reduced viral infectivity |
| Q92623235 | Dominant Negative MA-CA Fusion Protein Is Incorporated into HIV-1 Cores and Inhibits Nuclear Entry of Viral Preintegration Complexes |
| Q36434250 | Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain |
| Q34237075 | Fundamental differences between the nucleic acid chaperone activities of HIV-1 nucleocapsid protein and Gag or Gag-derived proteins: biological implications |
| Q33990752 | Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease |
| Q39226845 | Glyceraldehyde 3-phosphate dehydrogenase negatively regulates human immunodeficiency virus type 1 infection |
| Q24614498 | HIV type 1 Gag as a target for antiviral therapy |
| Q58597952 | HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites |
| Q38366763 | HIV-1 gag: an emerging target for antiretroviral therapy. |
| Q57050142 | High-resolution structures of HIV-1 Gag cleavage mutants determine structural switch for virus maturation |
| Q57459053 | Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation |
| Q30832180 | In vitro protease cleavage and computer simulations reveal the HIV-1 capsid maturation pathway |
| Q41735307 | Induced maturation of human immunodeficiency virus. |
| Q36884128 | Integrating the HIV-1 assembly/maturation pathway |
| Q35477673 | Lentiviral Gag assembly analyzed through the functional characterization of chimeric simian immunodeficiency viruses expressing different domains of the feline immunodeficiency virus capsid protein |
| Q30613887 | Maturation of the HIV-1 core by a non-diffusional phase transition. |
| Q59357414 | Modulation of the HIV nucleocapsid dynamics finely tunes its RNA-binding properties during virion genesis |
| Q33624690 | Novel approaches to inhibiting HIV-1 replication. |
| Q47109778 | Patterns of conserved gp120 epitope presentation on attached HIV-1 virions |
| Q41844750 | Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process |
| Q30049307 | Protein Interferon-Stimulated Gene 15 Conjugation Delays but Does Not Overcome Coronavirus Proliferation in a Model of Fulminant Hepatitis |
| Q40732172 | RNA and Nucleocapsid Are Dispensable for Mature HIV-1 Capsid Assembly |
| Q38393674 | Retroviral proteases and their roles in virion maturation |
| Q26752271 | Retrovirus maturation-an extraordinary structural transformation |
| Q92490664 | Second Generation Inhibitors of HIV-1 Maturation |
| Q36814171 | Site-selective probing of cTAR destabilization highlights the necessary plasticity of the HIV-1 nucleocapsid protein to chaperone the first strand transfer |
| Q33769181 | Structural analysis of HIV-1 maturation using cryo-electron tomography |
| Q28828191 | Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396 |
| Q35024116 | Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy |
| Q41682586 | The C-terminal domain of glyceraldehyde 3-phosphate dehydrogenase plays an important role in suppression of tRNALys3 packaging into human immunodeficiency virus type-1 particles |
| Q33919690 | The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. |
| Q33727091 | The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation |
| Q27009643 | The choreography of HIV-1 proteolytic processing and virion assembly |
| Q39621109 | Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity |
| Q52339521 | Transmission genetics of drug-resistant hepatitis C virus. |
Search more.